

# LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE", B/H. SATYAM COMPLEX, SCIENCE CITY ROAD, SOLA, AHMEDABAD-380 060.  
Tel. No. :- 079-67778000, Fax. No.-079-67778062. email id: info@lincolnpharma.com., CIN-L24230GJ1995PLC024288

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON 31.12.2014

(Rs. in Lacs)

PART - I												
PARTICULARS	CONSOLIDATED						STANDALONE					
	QUARTER ENDED			NINE MONTH ENDED		YEAR ENDED	QUARTER ENDED			NINE MONTH ENDED		YEAR ENDED
	31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014	31.12.2014	30.09.2014	31.12.2013	31.12.2014	31.12.2013	31.03.2014
	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
1	Income from operations											
(a)	6451.58	7591.09	5199.40	18737.62	14429.73	21126.69	5670.47	5789.52	5116.69	16097.05	14292.07	20849.02
(b)	301.45	214.32	95.34	731.79	421.30	171.61	259.08	188.88	81.35	644.86	381.83	142.33
	<b>6753.03</b>	<b>7805.41</b>	<b>5294.74</b>	<b>19469.41</b>	<b>14851.03</b>	<b>21298.30</b>	<b>5929.55</b>	<b>5978.40</b>	<b>5198.04</b>	<b>16741.91</b>	<b>14673.90</b>	<b>20991.35</b>
2	Expenses											
(a)	1213.99	1692.55	1077.58	4133.50	3145.84	5302.06	1088.57	1337.81	897.89	3395.86	2577.95	4125.27
(b)	3151.80	3794.70	2552.48	8219.47	6485.85	8989.80	2738.20	2570.18	2757.29	7010.58	7311.15	10578.20
(c)	99.17	-401.55	-120.34	-24.69	-352.31	-314.09	65.25	-353.70	-111.90	-69.77	-271.15	-209.31
(d)	472.20	439.44	485.44	1344.10	1422.95	1894.71	419.59	391.95	409.35	1191.09	1213.13	1618.77
(e)	112.31	132.04	91.47	355.63	264.77	352.65	71.00	91.46	59.98	233.25	170.85	227.94
(f)	1181.28	1081.96	605.33	3246.92	2420.44	3169.05	1057.50	1039.88	543.12	2945.36	2202.79	2865.74
	<b>6230.75</b>	<b>6739.14</b>	<b>4691.96</b>	<b>17274.93</b>	<b>13387.54</b>	<b>19394.18</b>	<b>5440.11</b>	<b>5077.58</b>	<b>4555.73</b>	<b>14706.37</b>	<b>13204.62</b>	<b>19206.61</b>
3	<b>522.28</b>	<b>1066.27</b>	<b>602.78</b>	<b>2194.48</b>	<b>1463.49</b>	<b>1904.12</b>	<b>489.44</b>	<b>900.82</b>	<b>642.31</b>	<b>2035.54</b>	<b>1469.28</b>	<b>1784.74</b>
4	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	<b>522.28</b>	<b>1066.27</b>	<b>602.78</b>	<b>2194.48</b>	<b>1463.49</b>	<b>1904.12</b>	<b>489.44</b>	<b>900.82</b>	<b>642.31</b>	<b>2035.54</b>	<b>1469.28</b>	<b>1784.74</b>
6	170.78	192.93	198.82	548.41	392.29	696.99	120.47	148.67	172.23	407.24	311.90	530.33
7	<b>351.50</b>	<b>873.34</b>	<b>403.96</b>	<b>1646.07</b>	<b>1071.20</b>	<b>1207.13</b>	<b>368.97</b>	<b>752.15</b>	<b>470.08</b>	<b>1628.30</b>	<b>1157.38</b>	<b>1254.41</b>
8	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9	<b>351.50</b>	<b>873.34</b>	<b>403.96</b>	<b>1646.07</b>	<b>1071.20</b>	<b>1207.13</b>	<b>368.97</b>	<b>752.15</b>	<b>470.08</b>	<b>1628.30</b>	<b>1157.38</b>	<b>1254.41</b>
10	99.64	147.91	106.30	364.99	188.67	88.55	131.17	87.08	342.29	72.50	111.65	
11	<b>251.86</b>	<b>725.43</b>	<b>297.66</b>	<b>1281.08</b>	<b>941.11</b>	<b>1018.46</b>	<b>280.42</b>	<b>620.98</b>	<b>383.00</b>	<b>1286.01</b>	<b>1084.88</b>	<b>1142.76</b>
12	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13	<b>251.86</b>	<b>725.43</b>	<b>297.66</b>	<b>1281.08</b>	<b>941.11</b>	<b>1018.46</b>	<b>280.42</b>	<b>620.98</b>	<b>383.00</b>	<b>1286.01</b>	<b>1084.88</b>	<b>1142.76</b>
14	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15	-7.11	26.15	-32.43	-0.01	-54.63	-46.96	0.00	0.00	0.00	0.00	0.00	0.00
16	<b>258.97</b>	<b>699.28</b>	<b>330.09</b>	<b>1281.09</b>	<b>995.74</b>	<b>1065.42</b>	<b>280.42</b>	<b>620.98</b>	<b>383.00</b>	<b>1286.01</b>	<b>1084.88</b>	<b>1142.76</b>
17	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08
18	-----	-----	-----	-----	-----	8250.16	-----	-----	-----	-----	-----	8281.66
19.i	1.59	4.29	2.02	7.85	6.10	6.53	1.72	3.81	2.35	7.88	6.65	7.01
19.ii	1.59	4.29	2.02	7.85	6.10	6.53	1.72	3.81	2.35	7.88	6.65	7.01
PART - II												
PARTICULARS OF SHAREHOLDING												
1	Public Shareholding:											
-Number of shares	11001573	10995779	10971449	11001573	10971449	10979649	11001573	10995779	10971449	11001573	10971449	10979649
-Percentage of Shareholding	67.45	67.41	67.26	67.45	67.26	67.32	67.45	67.41	67.26	67.45	67.26	67.32
2	Promoters and Promoter group Shareholding:											
a) Pledged/Encumbered												
-Number of shares	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
-Percentage of Shareholding (as a %of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
-Percentage of Shareholding (as a %of the total share capital of the Company)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
b) Non-encumbered												
-Number of shares	5309227	5315021	5339351	5309227	5339351	5331151	5309227	5315021	5339351	5309227	5339351	5331151
-Percentage of Shareholding (as a %of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
-Percentage of Shareholding (as a %of the total share capital of the Company)	32.55	32.59	32.74	32.55	32.74	32.68	32.55	32.59	32.74	32.55	32.74	32.68
Particulars	Quarter ended on 31.12.2014											
B	INVESTOR COMPLAINTS											
Pending at the beginning of the quarter	NIL											
Received during the quarter	3											
Disposed of during the quarter	3											
Remaining unresolved at the end of the quarter	NIL											

**NOTES:-**

- The above results were reviewed by the audit committee and approved by by the Board of Directors at its meeting held on 13.02.2015.
- Consequent to the applicability of the Companies Act, 2013 (the Act) to Accounting periods commencing on or after April 1, 2014 the Company has computed the depreciation charge for the quarter with reference to the estimated useful lives of the Fixed Assets as prescribed in schedule II of the Act. Further, Rs.73,98,875/- the carrying value (net of residual value) of assets whose remaining useful life is Nil as on 1st April, 2014 has been recognised in the opening balance of retained earnings.
- Previous year figures are regrouped/reclassified to confirm to the current year's presentation.
- Since the revenue from different segment is less than 10% of total revenue,segment wise results are not given.
- Statutory Auditors has carried out limited review for the quarterly result for quarter ended 31.12.2014.
- Pursuant to Clause 41 of the Listing Agreement, the Company has opted to publish the standalone financial results.

The consolidated results are being made available to the Stock Exchanges.

for LINCOLN PHARMACEUTICALS LIMITED

sd/-

(Mahendra G. Patel)  
Managing Director

Place : Ahmedabad.  
Date : 13.02.2015.

